Inside the Company That ’s Hot Wiring Vaccine Research in the Race to Combat the Coronavirus

Three months. That’s as long as Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, is willing to wait to get a vaccine candidate against the latest coronavirus that he can start testing in people. Since the virus was identified for the first time in people who fell ill with pneumonia-like symptoms in Wuhan, China, last December, the World Health Organization has declared this coronavirus outbreak, named 2019n-CoV, a public health emergency of international concern. In just over a month, more 11,000 people have tested positive for the virus in 18 countries, and more than 250 have died. When it comes to infectious diseases like this one, vaccines are the strongest weapons that health officials have. Getting vaccinated can protect people from getting infected in the first place, and if viruses or bacteria have nowhere to go, they have no way to spread from person to person. The problem is, vaccines take time to develop. Traditional methods, while extremely effective in controlling highly contagious diseases like measles, require growing large amounts of virus or bacteria, which takes months. Those microbes then become the key element in a vaccine — the so-called antigen that alerts the human immune system that some foreign interlopers have invaded the body and need to be evicted. However, researchers at Moderna Therapeutics, Cambridge, Mass., have developed a potential shortcut to this labor...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV coronavirus Infectious Disease Source Type: news

Related Links:

Authors: Petretto DR, Masala I, Masala C Abstract School closure and home confinement are two of the measures of lockdown chosen by governments and policymakers all over the world to prevent and limit the spread of the infection of COVID-19. There is still an open debate about the real effect of school closure on the reduction of risk of infection on children and the risk of infection on with other age groups (parents, grandparents and others). There is an agreement on the effect of school closure in reducing and delaying the peak of the outbreak. In this Editorial, starting from the ongoing Italian experience, we ...
Source: Clinical Practice and Epidemiology in Mental Health - Category: Psychiatry Tags: Clin Pract Epidemiol Ment Health Source Type: research
Authors: Conti P, Caraffa A, Tetè G, Gallenga CE, Ross R, Kritas SK, Frydas I, Younes A, Di Emidio P, Ronconi G Abstract SARS-CoV-2 virus is an infectious agent commonly found in certain mammalian animal species and today also in humans. SARS-CoV-2, can cause a pandemic infection with severe acute lung injury respiratory distress syndrome in patients with COVID-19, that can lead to patient death across all ages. The pathology associated with pandemic infection is linked to an over-response of immune cells, including virus-activated macrophages and mast cells (MCs). The local inflammatory response in the lung...
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
Publication date: Available online 19 September 2020Source: Respiratory InvestigationAuthor(s): J. Guiot, M. Henket, A.N. Frix, M. Delvaux, A. Denis, L. Giltay, M. Thys, F. Gester, M. Moutschen, J.L. Corhay, R. Louis, A. Ancion, A. Bouquegneau, C. Bovy, G. Darcis, J.O. Defraigne, B. Duysinx, A. Ghuysen, A. Gilbert, V. Heinen
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
Authors: Coste J, Bizouarn P, Leplège A PMID: 32948361 [PubMed - as supplied by publisher]
Source: Revue d Epidemiologie et de Sante Publique - Category: Epidemiology Tags: Rev Epidemiol Sante Publique Source Type: research
[To what extent Africa can limit the impact of the COVID-19 pandemic?] Rev Epidemiol Sante Publique. 2020 Sep 09;: Authors: Hoummadi L, Hafid J, Machraoui S, Admou B Abstract Following the onset of the global COVID-19 pandemic and the alerts issued by the World Health Organization, for several months attention has been focused on Africa as a potentially severely endangered continent. A sizable number of African countries, mainly low and middle income, suffer from limited available resources, especially in critical care, and COVID-19 is liable to overwhelm their already fragile health sys...
Source: Revue d Epidemiologie et de Sante Publique - Category: Epidemiology Tags: Rev Epidemiol Sante Publique Source Type: research
A new global study examining period life expectancy finds that the pandemic could lead to a short-term decline in life expectancy in many areas of the world.
Source: Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation business pharma Source Type: news
Publication date: Available online 19 September 2020Source: Pathology - Research and PracticeAuthor(s): Farahnaz Sadegh Beigee, Mihan Pourabdollah Toutkaboni, Neda Khalili, Seyed Alireza Nadji, Atosa Dorudinia, Mitra Rezaei, Elham Askari, Behrooz Farzanegan, Majid Marjani, Amir Rafiezadeh
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusions: The antiviral mouthwashes play a certainly important role in reducing the viral load of the salivary virus. In the present study, this importance could be proved in two different aspects, that is, the use of mouthwash before dental procedures to reduce the risk of transmission of the virus to the dental team and the use of this mouthwash in COVID-19 patients to help improve systemic problems associated with oral microbial flora. PMID: 32944152 [PubMed]
Source: Journal of Oral Microbiology - Category: Microbiology Tags: J Oral Microbiol Source Type: research
Publication date: Available online 14 August 2020Source: Journal of Emergency NursingAuthor(s): Yuli Hu, Lan Wang, Sanlian Hu, Fang Fang
Source: Journal of Emergency Nursing - Category: Nursing Source Type: research
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19. It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Allergy | Allergy & Immunology | Biology | China Health | Coronavirus | COVID-19 | Education | Emergency Medicine | Epidemics | Epidemiology | Genetics | Health | Infectious Diseases | International Medicine & Public Health | Measles | Measles Vaccine | National Institutes of Health (NIH) | Outbreaks | Pneomococcal Vaccine | Pneumonia | Vaccines | WHO